Immunocore Holdings plc Earnings Per Share (Basic)
Immunocore Holdings plc (IMCR) reported Earnings Per Share (Basic) of -$0.02 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- Immunocore Holdings plc earnings per share, basic for the quarter ending 2026-06-30 was -$0.02.
- Immunocore Holdings plc earnings per share, basic for the quarter ending 2026-03-31 was $0.26, a 160.00% increase year-over-year.
- Immunocore Holdings plc earnings per share, basic for the quarter ending 2025-12-31 was -$0.59.
- Immunocore Holdings plc earnings per share, basic for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Immunocore Holdings plc earnings per share, basic for fiscal 2025 was -$0.71.
- Immunocore Holdings plc earnings per share, basic for fiscal 2024 was -$1.02.
- Immunocore Holdings plc earnings per share, basic for fiscal 2023 was -$1.13.
- Immunocore Holdings plc earnings per share, basic for fiscal 2022 was -$1.15.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.02 10-Q · filed 2026-08-06 | $0.24 10-Q · filed 2026-08-06 | -$0.35 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.36 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | $0.26 10-Q · filed 2026-05-06 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.55 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$0.59 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$0.60 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$0.80 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.71 10-K · filed 2026-02-25 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | -$0.21 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.11 10-Q · filed 2025-11-06 | -$0.58 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$0.20 10-Q · filed 2026-08-06 | -$0.11 10-Q · filed 2026-08-06 | -$0.58 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | $0.10 10-Q · filed 2026-05-06 | -$0.37 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.43 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2024-12-31 | -$0.47 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$0.30 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$0.53 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$1.02 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.17 10-Q · filed 2025-11-06 | -$0.06 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$0.55 10-Q · filed 2025-11-06 | -$0.94 derived: net income ÷ weighted average shares · filed 2026-04-16 |
| 2024-06-30 | -$0.23 10-Q · filed 2025-08-07 | -$0.72 10-Q · filed 2025-08-07 | -$1.12 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$1.11 derived: net income ÷ weighted average shares · filed 2026-04-16 |
| 2024-03-31 | -$0.49 10-Q · filed 2025-05-07 | -$0.89 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$0.87 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$1.22 derived: net income ÷ weighted average shares · filed 2026-04-16 |
| 2023-12-31 | -$0.40 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$0.38 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$0.73 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$1.13 10-K · filed 2026-02-25 |
| 2023-09-30 | $0.02 10-Q · filed 2024-11-06 | -$0.33 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$0.73 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$0.35 10-Q · filed 2024-08-08 | -$0.75 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$0.40 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$1.15 10-K · filed 2025-02-26 | |||
| 2021-12-31 | -$4.24 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |